Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 433-240-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 24 AUG 1999 to 19 OCT 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 999
- Report date:
- 2000
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 27 JUL 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- 30 SEP 1996
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Test material form:
- solid: particulate/powder
- Details on test material:
- Batch: V.N0199.064
Expiry: 09.07.2001
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Recognized by international guidelines as the recommended test system
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: RCC Ltd, Biotechnology & Animal Breeding Division, Füllinsdorf /Switzerland
- Age at delivery: 6 weeks
- Weight at start of acclimatization: males: 120-157 g (mean 136 g), females: 96 - 144 g (mean 116 g)
- Fasting period before study: no data
- Housing: in groups of five in Makrolon type-4 cageswith wire mesh tops and standardized softwood bedding
- Diet: pelleted standard Provimi Kliba 3433 rat maintainace diet, ad libitum.
- Water: Community tap water, ad libitum
- Acclimation period: yes, 7 days
DETAILS OF FOOD AND WATER QUALITY: The feed batch and tap water were analysed for contaminants. None of the contaminants analysed in the water and diet is considered to have been present at a concentration which would have affected the validity of the results.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +- 3
- Humidity (%): 40-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG300
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test article formulations were prepared weekly. Test substance was weighed into a glass beaker an a tared Mettler Balance and the vehicle added. The mixtures were prepared using a magnetic stirrer and stored at room temperature (17 - 23°C).
Homogeneity of the test article in the vehicle were maintained during the daily administration period using a magnetic stirrer.
VEHICLE
- Justification for use and choice of vehicle (if other than water): PEG 300 was found to yield the most homogenous test article/vehicle mixture
- Concentration in vehicle: 0, 5, 20 or 100 mg/mL
- Amount of vehicle (if gavage): 10 ml/kg bw/d
- Lot/batch no. (if required): 395304/1 30699 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability (after 2 hours and 7 days) of the dose formulations were determined in samples taken during acclimatization. Concentration and homogeneity of the dose formulations were determined in samples taken during week 3 of the treatment. The analyses were performed by RCC Ltd (Environmental Chemistry & Pharmanalytics Division) according to a photometric measurement method supplied by the Sponsor.
- Duration of treatment / exposure:
- 28 days for exposure groups 1-4 (0, 50, 200 and 1000 mg/kg bw/d, consisting of 5 male and 5 female animals respectively)
Two additional exposure groups (0 and 1000 mg/kg bw/d, 5 male and 5 female animals/ exposure group) were exposed for 28 days followed by a recovery period of 14 days. - Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 0 and 1000 mg/kg bw/d: 10 males and 10 females
50 and 200 mg/kg bw/d: 5 male and 5 females - Control animals:
- yes, concurrent vehicle
- yes, historical
- Details on study design:
- - Dose selection rationale: Based on the results of a non-GLP 5-day dose-range-finding study in which the test substance was administerd by gavage to 2 rats per group and sex. Animals showed only passive effects to the treatment ( yellow colored feces)
- Rationale for animal assignment: computer generated random algorithm - Positive control:
- none
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE:
recorded once during pre-test period, and weekly thereafter
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after week 4 and after week 6
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: Yes for 18 h
- How many animals: all
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: after week 4 and after week 6
- Animals fasted: Yes for 18 h
- How many animals: all
URINALYSIS: Yes
- Time schedule for collection of urine: after week 4 and after week 6
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes for 18 h, during this time urine was collected
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: during week 4
- Dose groups that were examined: all animals evaluated
- Battery of functions tested: grip strength and locomotor activity
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- The following statistical methods were used to analyze grip strength, locomotor activity, body weights, organ weights and all ratios, as well as clinical laboratory data :
- The Dunnett-test (many to one t-test) based an a pooled variance estimate was applied if the variables could be assumed to follow a normal distribution for the comparison of the treated groups and the control groups for each sex.
- The Steel-test (many-one rank test) was applied instead of the Dunnett-test when the data could not be assumed to follow a normal distribution.
- Student's t-test was applied to grip strength and locomotor activity.
- Fisher's exact-test was applied to macroscopic findings.
References :
- C.W. Dunnett: A Multiple Comparison Procedure for Comparing Several Treatments with a Control, J. Amer. Stat. Assoc. 50, 1096-1121 (1955).
- R.G. Miller: Simultaneous Statistical Inference, Springer Verlag, New York (1981).
- R.A. Fisher: Statistical Methods for Research Workers, Oliver and Boyd, Edinburgh (1950).
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- GENERAL CAGESIDE OBSERVATIONS (DAILY)
No test article-related clinical signs were evident at any dose level.
Yellow feces was noted in all test article-treated animals. The severity of the discoloration was related to dose and persisted during the first few days of recovery in the remaining animals treated with 1000 mg/kg/day. Discoloration of the feces is considered to be a common passive effect resulting from oral administration of a dyestuff and does not reflect a toxic response.
Slightly soft feces were noted in all animals from treatment day 2 until the last day of treatment. This finding persisted during the first few days of recovery in the remaining animals of the control group and in animals treated with 1000 mg/kg/day. Soft feces is known to be a common effect caused by PEG 300 and is unrelated to the test article.
DETAILED CLINICAL OBSERVATIONS (WEEKLY)
Reduced grooming was noted during treatment week 1 in all females treated with 50 mg/kg/day. The push-off reflex was reduced during week 1 in one female ( treated with 1000 mg/kg/day.
Slight chromodacryorrhea was noted during treatment week 1 in one male rat treated with 1000 mg/kg/day.
These findings were considered to be incidental and unrelated to the treatment with the test article.
All other animals were without clinical signs during pretest and during treatment weeks 1-3. - Mortality:
- no mortality observed
- Description (incidence):
- All animals survived until scheduled necroscopy.
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No test article-related differences to the control values were noted at any dose level. The few statistically significant differences were considered to be incidental.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Plasma uric acid levels were higher in males and females treated with the test article at 1000 mg/kg/day. Although the differences to the control values attained statistical significance (males, p<0.01; females p<0.05), they were within the upper range of the 95% confidence limits of the historical control data and therefore considered to be unrelated to the test article treatment.
The remaining differences to the control values noted in the males treated with 1000 mg/kg/day (higher total bilirubin, sodium, albumin and total protein) were not evident in the females, nor were corresponding findings noted in related parameters. These differences were considered to be incidental. - Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Slight chromodacryorrhea was noted in one male rat during functional observational battery at treatment week 4. This finding was not seen in the remaining males or females of this group and therefore considered to be incidental.
All other animals were without clinical signs during treatment week 4.
The forelimb grip strength of the test article-treated animals was similar to that of the controls.
The hindlimb grip strength of the males treated with 200 mg/kg/day or 1000 mg/kg/day was higher than that of the controls, and attained statistical significance (p<0.01). These differences were considered to be unrelated to the test article.
The hind limb grip strength of the test article-treated females compared favorably with that of the control females.
Locomotor Activity
No test article-related differences in locomotor activity were noted when compared with the control values. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- After 4 Weeks
No test article-related differences to the control values were noted at any dose level tested.
The statistically significant higher absolute brain weight (p<0.05) noted in the males treated with 1000 mg/kg/day was considered to be incidental. Subsequently, the brain-to-kidney weight ratio noted in these animals was slightly lower. This difference to the control value attained statistical significance (p<0.05).
All other organ weights and ratios compared favorably with the controls.
After 6 Weeks
The absolute mean liver and testes weights of males treated with 1000 mg/kg/day were higher than those of the control males. The differences attained statistical significance (p<0.05), but were considered to be incidental. The absolute mean liver weight of test article-treated females compared favorably with that of the control females.
All other organ weights compared favorably with those of the controls. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- All findings were considered to be within the range of spontaneous background alterations in rats of this strain and age. They consisted of incompletely collapsed lungs, renal pelvis dilation, accentuated lobular pattern of the liver or size reduction of a liver lobe, enlarged adrenal glands, uterus horn dilation and discoloration and/or discolored foci in several organs. In one kidney, a nodule was recorded.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A malignant nephroblastoma was the histological correlate to the nodule noted in the kidney of one control male. This tumor and the rernaining findings were within the range of spontaneous background lesions recorded in rats of this strain and age.
- Other effects:
- not examined
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- other: no adverse effects up to the highest dose tested (i.e. also limit dose for testing)
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- In this 28-day study according to OECD guideline 407 performed under GLP, male and female Wistar rats were exposed to 0, 50, 200 or 1000 mg test item/kg bw/d in PEG 300 via gavage. Cage side observations, clinical observations, food consumption, body weight development, haematology, urine analysis, macroscopic investigations, histopathology of selected organs and assays concerning the functional observational battery (grip strength and locomotor activity) did not reveal any substance related toxic effects, except for a yellow discoloration of the feces, higher plasma uric acid levels in males and females treated with the test article at 1000 mg/kg/day and a higher absolute brain weight noted in the males treated with 1000 mg/kg/day. However, these effects were considered incidential by the study authors. These effects were minimal and therefore not accounted for as adverse. The NOAEL in this study was 1000 mg/kg bw/d.
- Executive summary:
The test item did not reveal substance related adverse effects under the conditions tested (according to OECD TG 407, performed under GLP). Yellow feces was noted in all test article-treated animals. Discoloration of the feces is considered to be a common passive effect resulting from oral administration of a dyestuff and does not reflect a toxic response.
Minimal effects were observed in the highest dose group, but considered to be incidental. Plasma uric acid levels were higher in males and females treated with the test article at 1000 mg/kg/day. Although the differences to the control values attained statistical significance (males, p<0.01; females p<0.05), they were within the upper range of the 95% confidence limits of the historical control data and therefore considered to be unrelated to the test article treatment. The statistically significant higher absolute brain weight (p<0.05) noted in the males treated with 1000 mg/kg/day was considered to be incidental, too.
Therefore the NOAEL in this subacute oral feeding study was 1000 mg/kg bw/d, the highest dose tested.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.